Fiche publication
Date publication
septembre 2026
Journal
JHEP reports : innovation in hepatology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BRONOWICKI Jean-Pierre
,
Dr JEULIN Hélène
Tous les auteurs :
Haghnejad V, Lucas M, Jacquinot N, Jeulin H, Daude S, Bensenane-Oussalah M, Schvoerer E, Bernard Y, Luc A, Bronowicki JP
Lien Pubmed
Résumé
Patients with cirrhosis show impaired immune responses to standard intramuscular (IM) hepatitis B virus (HBV) vaccination, resulting in low seroconversion rates. Intradermal (ID) vaccination and topical imiquimod have been proposed as strategies to enhance vaccine immunogenicity. We conducted a randomized controlled pilot trial to compare three HBV revaccination strategies in patients with advanced chronic liver disease (ACLD) who previously failed standard IM vaccination: IM revaccination, ID revaccination, and ID revaccination combined with imiquimod (ID+IMQ). The primary endpoint was seroconversion at Month 7, defined as anti-HBs titres ≥10 mIU/mL.
Mots clés
Immune Response, Immunogenicity, Immunomodulation, Randomized Controlled Trial, Topical Administration, Treatment Outcome, Vaccination Failure, Vaccine
Référence
JHEP Rep. 2026 09 21;:102039
